Incyte Corporation $INCY Stock: Profund Advisors LLC Raises Stake

Profund Advisors LLC grew its position in shares of Incyte Corporation (NASDAQ:INCY) by 30.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 19,152 shares of the biopharmaceutical company’s stock after buying an additional 4,430 shares during the quarter. Profund Advisors LLC’s holdings in Incyte were worth $2,324,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Fiduciary Financial Advisors bought a new position in Incyte in the 2nd quarter valued at approximately $26,000. Continuum Advisory LLC purchased a new stake in Incyte during the 2nd quarter valued at $36,000. Latitude Advisors LLC bought a new stake in shares of Incyte in the 3rd quarter worth $39,000. Quantbot Technologies LP bought a new stake in shares of Incyte in the 2nd quarter worth $52,000. Finally, Parkside Financial Bank & Trust increased its holdings in shares of Incyte by 49.0% in the 2nd quarter. Parkside Financial Bank & Trust now owns 727 shares of the biopharmaceutical company’s stock worth $82,000 after purchasing an additional 239 shares in the last quarter. Institutional investors own 96.97% of the company’s stock.

Incyte News Summary

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Incyte reported third-quarter revenue of $1.56 billion, up 14% year over year and above the $1.46 billion analyst estimate. Adjusted loss of $3.60 per share was narrower than expected, helping support the stock. INCY Q3 Loss Narrower Than Expected, Sales Beat, FY’26 View Raised
• Positive Sentiment: The company raised 2026 total net-sales guidance to $5.21 billion-$5.30 billion, from $5.13 billion-$5.26 billion previously. Opzelura guidance was also increased to $1.10 billion-$1.12 billion, reflecting continued demand. Incyte signals 2026 net sales outlook as Opzelura guidance rises
• Positive Sentiment: Product trends were favorable: Opzelura sales rose 36% to $255 million, while hematology and oncology portfolio sales increased 38% to $235 million. Jakafi and Jakafi XR sales grew 4% to $827 million. Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales Guidance
• Positive Sentiment: Barclays raised its price target from $139 to $143 and maintained an “overweight” rating, implying substantial upside and reinforcing the bullish reaction. Barclays Incyte analyst recommendation
• Neutral Sentiment: Wells Fargo lowered its target slightly to $127 and kept an “equal weight” rating, while RBC raised its target to $117 but retained a “sector perform” rating. The changes indicate limited conviction among some analysts. Wells Fargo Incyte analyst recommendation
• Negative Sentiment: Incyte posted a GAAP loss largely because of a $1.23 billion in-process research and development charge tied to the Vega Therapeutics acquisition. The unusual charge obscures underlying operating strength and may keep investors focused on acquisition execution. Incyte Posts Q3 Loss on Vega Acquisition Charge

Insider Transactions at Incyte

In other Incyte news, insider Pablo Cagnoni sold 10,801 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the completion of the sale, the insider directly owned 183,200 shares in the company, valued at $23,002,592. The trade was a 5.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 16.20% of the company’s stock.

Incyte Price Performance

INCY stock opened at $120.39 on Monday. The company has a market cap of $24.54 billion, a P/E ratio of 64.04, a price-to-earnings-growth ratio of 4.99 and a beta of 0.78. Incyte Corporation has a 1 year low of $89.25 and a 1 year high of $132.60. The stock’s fifty day moving average price is $120.49 and its 200-day moving average price is $108.14.

Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, topping the consensus estimate of ($3.93) by $0.33. The company had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.46 billion. Incyte had a return on equity of 7.92% and a net margin of 6.71%. Incyte’s revenue was up 14.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.26 earnings per share. As a group, analysts expect that Incyte Corporation will post 1.97 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Oppenheimer set a $152.00 price target on Incyte in a report on Tuesday, October 27th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Incyte in a report on Friday, September 11th. Royal Bank Of Canada boosted their target price on Incyte from $114.00 to $117.00 and gave the stock a “sector perform” rating in a research report on Friday. Mizuho upped their target price on shares of Incyte from $121.00 to $137.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Finally, TD Cowen raised their price target on shares of Incyte from $138.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, October 21st. Twelve equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $132.90.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.